AR118839A1 - Formas sólidas de un inhibidor de glyt1 - Google Patents
Formas sólidas de un inhibidor de glyt1Info
- Publication number
- AR118839A1 AR118839A1 ARP200101242A ARP200101242A AR118839A1 AR 118839 A1 AR118839 A1 AR 118839A1 AR P200101242 A ARP200101242 A AR P200101242A AR P200101242 A ARP200101242 A AR P200101242A AR 118839 A1 AR118839 A1 AR 118839A1
- Authority
- AR
- Argentina
- Prior art keywords
- ppm
- solid forms
- solid
- inhibitor
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Formas sólidas de un inhibidor del transportador de glicina-1 (GlyT1). También métodos para fabricar estas formas sólidas, composiciones farmacéuticas que comprenden estas formas sólidas y su uso para afecciones médicas que responden al tratamiento con un inhibidor del transportador de glicina-1. Reivindicación 1: Una Forma sólida I del Compuesto 1 que tiene la fórmula estructural (1) en donde la Forma I del Compuesto 1 caracterizada porque: al menos tres picos de XRPD en 2Q ángulos seleccionados de 4,6º, 10,0º, 16,7º, 18,0º, 19,0º, 20,0º y 22,7º; o al menos tres picos de resonancia magnética nuclear de ¹³C en estado sólido en los desplazamientos químicos seleccionados de 131,5 ppm, 127,2 ppm, 28,7 ppm y 25,7 ppm; o al menos tres picos de resonancia magnética nuclear de ¹⁹F en estado sólido en los desplazamientos químicos seleccionados de -64,3, -64,8, -65,9, -66,8, -78,0, -78,5, -79,3 y -80,0 ppm.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841401P | 2019-05-01 | 2019-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR118839A1 true AR118839A1 (es) | 2021-11-03 |
Family
ID=70740812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101242A AR118839A1 (es) | 2019-05-01 | 2020-04-30 | Formas sólidas de un inhibidor de glyt1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11447474B2 (es) |
| EP (1) | EP3962911A1 (es) |
| JP (2) | JP7513349B2 (es) |
| KR (1) | KR20220004174A (es) |
| CN (1) | CN113784966B (es) |
| AR (1) | AR118839A1 (es) |
| AU (1) | AU2020266566A1 (es) |
| BR (1) | BR112021020883A2 (es) |
| CA (1) | CA3138288A1 (es) |
| CL (1) | CL2021002837A1 (es) |
| CO (1) | CO2021014260A2 (es) |
| CR (1) | CR20210545A (es) |
| DO (1) | DOP2021000224A (es) |
| EA (1) | EA202192925A1 (es) |
| EC (1) | ECSP21082195A (es) |
| IL (1) | IL287630A (es) |
| JO (1) | JOP20210295A1 (es) |
| MA (1) | MA55801A (es) |
| MX (1) | MX2021013341A (es) |
| PE (1) | PE20212263A1 (es) |
| SG (1) | SG11202111972YA (es) |
| TW (1) | TW202106680A (es) |
| WO (1) | WO2020223419A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7930336B2 (en) | 2006-12-05 | 2011-04-19 | Altera Corporation | Large multiplier for programmable logic device |
| CA3166938A1 (en) | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| WO2022034146A1 (en) * | 2020-08-13 | 2022-02-17 | Boehringer Ingelheim International Gmbh | Treatment of cognitive impairement associated with schizophrenia |
| EP4229051A1 (en) | 2020-10-13 | 2023-08-23 | Boehringer Ingelheim International GmbH | Process of reworking |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL65843A (en) * | 1977-08-11 | 1986-12-31 | American Cyanamid Co | Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type |
| ES2634841T3 (es) * | 2003-10-14 | 2017-09-29 | Pfizer Products Inc. | Derivados bicíclicos [3.1.0] como inhibidores del transportador de glicina |
| CA2745690A1 (en) * | 2008-12-04 | 2010-06-10 | Evgeny Zlotinikov | Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative |
| WO2010078348A1 (en) * | 2008-12-29 | 2010-07-08 | Vanderbilt University | 3.1.0 bicyclic glyt1 inhibitors and methods of making and using same |
| US9012489B2 (en) | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| US10919891B2 (en) | 2017-04-27 | 2021-02-16 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
-
2020
- 2020-04-30 JO JOP/2021/0295A patent/JOP20210295A1/ar unknown
- 2020-04-30 CA CA3138288A patent/CA3138288A1/en active Pending
- 2020-04-30 WO PCT/US2020/030580 patent/WO2020223419A1/en active Application Filing
- 2020-04-30 KR KR1020217039503A patent/KR20220004174A/ko unknown
- 2020-04-30 JP JP2021563717A patent/JP7513349B2/ja active Active
- 2020-04-30 MA MA055801A patent/MA55801A/fr unknown
- 2020-04-30 SG SG11202111972YA patent/SG11202111972YA/en unknown
- 2020-04-30 DO DO2021000224A patent/DOP2021000224A/es unknown
- 2020-04-30 AU AU2020266566A patent/AU2020266566A1/en active Pending
- 2020-04-30 US US16/862,608 patent/US11447474B2/en active Active
- 2020-04-30 CN CN202080032902.7A patent/CN113784966B/zh active Active
- 2020-04-30 CR CR20210545A patent/CR20210545A/es unknown
- 2020-04-30 AR ARP200101242A patent/AR118839A1/es unknown
- 2020-04-30 EP EP20726654.5A patent/EP3962911A1/en active Pending
- 2020-04-30 MX MX2021013341A patent/MX2021013341A/es unknown
- 2020-04-30 BR BR112021020883A patent/BR112021020883A2/pt unknown
- 2020-04-30 TW TW109114685A patent/TW202106680A/zh unknown
- 2020-04-30 PE PE2021001800A patent/PE20212263A1/es unknown
- 2020-04-30 EA EA202192925A patent/EA202192925A1/ru unknown
-
2021
- 2021-10-26 CO CONC2021/0014260A patent/CO2021014260A2/es unknown
- 2021-10-27 IL IL287630A patent/IL287630A/en unknown
- 2021-10-28 CL CL2021002837A patent/CL2021002837A1/es unknown
- 2021-11-17 EC ECSENADI202182195A patent/ECSP21082195A/es unknown
-
2022
- 2022-06-27 US US17/849,935 patent/US20220332710A1/en active Pending
-
2024
- 2024-05-02 JP JP2024074707A patent/JP2024100792A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022530630A (ja) | 2022-06-30 |
| JOP20210295A1 (ar) | 2023-01-30 |
| AU2020266566A1 (en) | 2021-11-11 |
| WO2020223419A1 (en) | 2020-11-05 |
| IL287630A (en) | 2021-12-01 |
| CR20210545A (es) | 2021-12-23 |
| CO2021014260A2 (es) | 2021-10-29 |
| ECSP21082195A (es) | 2021-12-30 |
| JP7513349B2 (ja) | 2024-07-09 |
| MA55801A (fr) | 2022-03-09 |
| BR112021020883A2 (pt) | 2022-04-19 |
| KR20220004174A (ko) | 2022-01-11 |
| CN113784966B (zh) | 2024-07-19 |
| EP3962911A1 (en) | 2022-03-09 |
| TW202106680A (zh) | 2021-02-16 |
| SG11202111972YA (en) | 2021-11-29 |
| JP2024100792A (ja) | 2024-07-26 |
| MX2021013341A (es) | 2021-11-17 |
| CN113784966A (zh) | 2021-12-10 |
| DOP2021000224A (es) | 2021-12-15 |
| US20220332710A1 (en) | 2022-10-20 |
| US20200347041A1 (en) | 2020-11-05 |
| PE20212263A1 (es) | 2021-11-29 |
| CL2021002837A1 (es) | 2022-07-29 |
| CA3138288A1 (en) | 2020-11-05 |
| US11447474B2 (en) | 2022-09-20 |
| EA202192925A1 (ru) | 2022-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR118839A1 (es) | Formas sólidas de un inhibidor de glyt1 | |
| CL2020003102A1 (es) | Molécula que tiene utilidad pesticida, y composiciones y procedimientos relacionados con la misma. | |
| BR112015022456A2 (pt) | síntese de líquidos iônicos de compostos derivados de lignina | |
| AR087715A1 (es) | Anticuerpos anti pcsk9 y usos de los mismos | |
| AR086254A1 (es) | Derivados de imidazol utiles para el tratamiento de artritis | |
| DOP2010000323A (es) | Pirimidin-5-carboxamidas sustituidas 281 | |
| CL2019003324A1 (es) | Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745) | |
| CO6700838A2 (es) | Compuestos sustituidos de banzamida | |
| AR102362A1 (es) | Compuestos de metil-piperidina útiles para inhibir la sintasa-1 de prostaglandina microsomal e2 | |
| AR082825A2 (es) | Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios | |
| CL2009000882A1 (es) | Un compuesto n-(4-cloro-3-(piridin-2-il)fenil)-4-(2-hidroxi-2-metilpropilsulfonil)-2-metilbenzamida, inhibidor de la via de señalización hedgehog; composición farmacéutica que comprende a dicho compuesto; y su uso para tratar el cancer. | |
| AR088755A1 (es) | Formas solidas de un inhibidor de disociacion transtiretina | |
| CY1126067T1 (el) | Συντηγμενες πυρρολινες που δρουν σαν ειδικοι για ουβικιτινη αναστολεις πρωτεασης 30 (usp30) | |
| DOP2014000048A (es) | Composiciones farmacéuticas que comprenden un polisacárido y un inhibidor hdac | |
| NZ726947A (en) | Molecules having certain pesticidal utilities, intermediates, compositions, and processes, related thereto | |
| AR043444A1 (es) | Profarmacos de diaril-2- 5h -furanonas que liberan oxido nitrico como inhibidores de la ciclooxigenasa-2 | |
| SV2018005702A (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| BR112013002229A2 (pt) | "parículas de epóxi éster vinílicas reticuladas modificadas com elastômero e métodos para produção e uso das mesmas" | |
| AR093738A1 (es) | Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos | |
| UY32954A (es) | PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?. | |
| AR084051A1 (es) | Derivados de 1-hidroxi-2-oxo-hidroquinolina, composiciones farmaceuticas que los contienen y uso de los mismos para tratar deficits cognitivos asociados con esquizofrenia y otros trastornos psiquiatricos y/o neurologicos | |
| BR112014000697A2 (pt) | processo e éster vinílico | |
| CL2019001623A1 (es) | Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor. | |
| PE20160849A1 (es) | Formulaciones de inyeccion con base en aceite de sesamo | |
| AR093703A1 (es) | Agente profilactico o terapeutico para el sindrome de sjogren |